Intraarticular Wnt Inhibitor Therapy Effective in Knee Osteoarthritis Save
At the 2016 World Congress on Osteoarthritis (OARSI) meeting last week, first line results of a novel intraarticular inhibitor of the Wnt pathway (SM04690) in knee osteoarthritis were presented.
This phase 1 clinical trial showed that 12 weeks after intraarticular treatment, subjects treated with SM04690 (0.07mg) were more likely to achieve an OMERACT-OARSI strict therapeutic response than placebo. The Strict Responder criterion is a composite of multiple osteoarthritis pain or function evaluations of the subject resulting in a binary assessment of whether a clinically-relevant improvement is achieved as a result of the treatment.
12 weeks after the injection, 76% of the patients who received 0.07 mg of SM04690 (N=17) achieved strict OMERACT-OARSI response compared to 36% of the patients who received placebo (N=11).
Structural improvements were observed in preclinical models of osteoarthritis of the knee, such as an increase in cartilage thickness, a decrease in fissures, and remodeling of subchondral bone, after a single intra-articular injection of SM04690.
A Phase 2 study of SM04690 (NCT02536833) in patients with knee OA is currently in progress.
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.